Revolution Medicines, Inc. $RVMD Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 36.2% during the second quarter, HoldingsChannel.com reports. The firm owned 3,843,415 shares of the company’s stock after selling 2,184,404 shares during the period. Wellington Management Group LLP’s holdings in Revolution Medicines were worth $719,795,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Contravisory Investment Management Inc. purchased a new stake in shares of Revolution Medicines during the 2nd quarter valued at $32,000. Global Retirement Partners LLC raised its position in shares of Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares during the period. Torren Management LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth $33,000. Johnson Financial Group Inc. acquired a new position in Revolution Medicines in the second quarter valued at $37,000. Finally, Arax Advisory Partners acquired a new position in Revolution Medicines in the fourth quarter valued at $38,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Buying and Selling

In other news, insider Mark A. Goldsmith sold 80,000 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the sale, the insider owned 267,330 shares in the company, valued at approximately $55,925,436. This trade represents a 23.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Margaret A. Horn sold 29,600 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $160.12, for a total value of $4,739,552.00. Following the completion of the sale, the chief operating officer owned 154,647 shares of the company’s stock, valued at approximately $24,762,077.64. This trade represents a 16.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wedbush boosted their price target on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday. HC Wainwright lifted their price objective on Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler boosted their target price on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $248.00 target price on shares of Revolution Medicines in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $198.89.

Revolution Medicines Stock Down 6.0%

Shares of Revolution Medicines stock opened at $207.88 on Friday. The company has a fifty day moving average price of $193.33 and a 200 day moving average price of $148.59. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a twelve month low of $37.56 and a twelve month high of $224.31. The stock has a market cap of $44.56 billion, a price-to-earnings ratio of -23.57 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the business posted ($1.31) earnings per share. Equities research analysts forecast that Revolution Medicines, Inc. will post -8.85 earnings per share for the current fiscal year.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.